Suggestions
Vikramjit Chopra
Business Development and Regulatory Affairs Consultant at Fusion Genomics Corporation
Professional Background
Vikramjit Chopra is a remarkable life sciences and business professional with a dynamic career that spans multiple sectors, including health research, biotechnology, and corporate strategy. With a strong foundation in life sciences research, Vikramjit's expertise encompasses diagnostics and therapeutic developments that hold significant commercial potential. His extensive experience collaborating with both public and private health organizations allows him to disseminate vital knowledge among industry leaders and stakeholders, cementing his role as a catalyst for advancement in the life sciences sector.
In his current role as the Precision Medicine Program Manager at Genome Canada Transplant Consortium, Vikramjit leads initiatives designed to improve patient outcomes through the integration of precision medicine approaches in transplant science. His responsibilities involve steering research programs, engaging with cross-functional teams, and driving innovative solutions in the realm of genomics and patient care. His impressive resume showcases his ability to identify new and emerging technologies, develop strategic partnerships, and translate science into viable commercial opportunities.
Education and Achievements
Vikramjit has an impressive academic background that has equipped him with a versatile skill set essential for success in the highly competitive landscape of life sciences. He earned his MBA with a focus on Management of Technology from Simon Fraser University, which provides him with an essential blend of business acumen and technical expertise. Prior to his MBA, he completed a Doctor of Philosophy (Ph.D.) in Medical Genetics at The University of British Columbia, where he focused on groundbreaking research in genetics that continues to impact contemporary studies in precision medicine.
His academic journey also includes a Master’s degree in Neurology and Neurosurgery from McGill University, where he honed critical research skills that contribute to his work in enhancing therapeutic approaches in neurological disorders. Vic, as his colleagues affectionately call him, began his academic pursuits with a Bachelor's degree in Microbiology and Immunology, also from McGill University, providing him with a strong base in the biological sciences that has continually informed his career trajectory.
Achievements
Vikramjit Chopra boasts an array of professional achievements across several organizations. He has held prominent roles that highlight his leadership and collaborative skills, most notably as a Business Development and Regulatory Affairs Consultant at Fusion Genomics Corporation. In this capacity, he played a pivotal role in navigating the complex regulatory landscape of biotechnology while enabling business development initiatives that promote strategic growth in the industry.
Before this, Vikramjit contributed as a Business Consultant at VSC Bio Consulting, where he supported a variety of biotechnology firms in achieving their strategic goals through tailored consulting services. His analytical approach and innovative strategies have had lasting impacts on the projects he has led and consulted for.
Vikramjit started his journey at Genome British Columbia as a Research Program Manager, where he was instrumental in managing significant research initiatives that advanced understanding in genetics and their applications in health. His tenure also includes valuable experiences as an Internship Proposal Reviewer at MITACS and as a Research Associate at the BC Mental Health and Addiction Research Institute, further demonstrating his dedication to advancing public health initiatives.
His postdoctoral fellowship at Canada's Michael Smith Genome Sciences Centre, part of the BC Cancer Agency, exemplifies his commitment to research excellence in genomics, focusing on cancer-related studies that have implications for both research and therapeutic development. Vikramjit’s career is a testament to his ability to bridge the gap between scientific understanding and commercial viability, making him a valuable asset to the life sciences community.